Evidence map›Paper›PMID 26898755›Full record

ArticleOncogene2016

Threonine 209 phosphorylation on RUNX3 by Pak1 is a molecular switch for its dualistic functions.

A Kumar, M Singhal, C Chopra, S Srinivasan, R P Surabhi, R Kanumuri, S Tentu, S Jagadeeshan, S Sundaram, K Ramanathan and 6 more

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.3field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 1 country.

A KumarDepartment of Biotechnology, Indian Institute of Technology Madras (IITM), Chennai, India.
M SinghalDepartment of Biotechnology, Indian Institute of Technology Madras (IITM), Chennai, India.
C ChopraDepartment of Biotechnology, Indian Institute of Technology Madras (IITM), Chennai, India.
S SrinivasanDepartment of Biotechnology, Indian Institute of Technology Madras (IITM), Chennai, India.
R P SurabhiDepartment of Biotechnology, Indian Institute of Technology Madras (IITM), Chennai, India.
R KanumuriDepartment of Biotechnology, Indian Institute of Technology Madras (IITM), Chennai, India.
S TentuDepartment of Biotechnology, Indian Institute of Technology Madras (IITM), Chennai, India.
S JagadeeshanDepartment of Biotechnology, Indian Institute of Technology Madras (IITM), Chennai, India.
S SundaramDepartment of Pathology, Sri Ramachandra University, Chennai, India.
K RamanathanDepartment of Pathology, Sri Ramachandra University, Chennai, India.
R Shankar PitaniDepartment of Community Medicine, Sri Ramachandra University, Chennai, India.
B MuthuswamyMadras Diabetic Research Foundation (MDRF), Chennai, India.
S AbhijitMadras Diabetic Research Foundation (MDRF), Chennai, India.
A S NairRajiv Gandhi Centre for Biotechnology (RGCB), Thiruvananthapuram, India.
G VenkatramanDepartment of Human Genetics, Sri Ramachandra University, Chennai, India.
S K RayalaDepartment of Biotechnology, Indian Institute of Technology Madras (IITM), Chennai, India.
Indian Institute of Technology Madras · INSri Ramachandra Institute of Higher Education and Research · INMadras Diabetes Research Foundation · INRajiv Gandhi Centre for Biotechnology · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

P21 Activated Kinase 1 (Pak1), an oncogenic serine/threonine kinase, is known to have a significant role in the regulation of cytoskeleton and cellular morphology. Runx3 was initially known for its role in tumor suppressor function, but recent studies have reported the oncogenic role of Runx3 in various cancers. However, the mechanism that controls the paradoxical functions of Runx3 still remains unclear. In this study, we show that Runx3 is a physiologically interacting substrate of Pak1. We identified the site of phosphorylation in Runx3 as Threonine 209 by mass spectrometry analysis and site-directed mutagenesis, and further confirmed the same with a site-specific antibody. Results from our functional studies showed that Threonine 209 phosphorylation in Runx3 alters its subcellular localization by protein mislocalization from the nucleus to the cytoplasm and subsequently converses its biological functions. This was further supported by in vivo tumor xenograft studies in nude mouse models which clearly demonstrated that PANC-28 cells transfected with the Runx3-T209E clone showed high tumorigenic potential as compared with other clones. Our results from clinical samples also suggest that Threonine 209 phosphorylation by Pak1 could be a potential therapeutic target and of great clinical relevance with implications for Runx3 inactivation in cancer cells where Runx3 is known to be oncogenic. The findings presented in this study provide evidence of Runx3-Threonine 209 phosphorylation as a molecular switch in dictating the tissue-specific dualistic functions of Runx3 for the first time.

Indexed as

AnimalsBiomarkers, TumorCell Line, TumorCell NucleusCore Binding Factor Alpha 3 SubunitCytoplasmFemaleGene Expression Regulation, NeoplasticHumansIntracellular Signaling Peptides and ProteinsMiceMutagenesis, Site-DirectedNeoplasmsPhosphorylationThreonineXenograft Model Antitumor AssaysBiomarkers, TumorCore Binding Factor Alpha 3 SubunitIntracellular Signaling Peptides and ProteinsPAK1IP1 protein, humanRunx3 protein, humanThreonine

Identifiers

PMID26898755
OpenAlexW2277618071

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.